Pharming (PHAR) Income from Continuing Operations (2020 - 2026)
Pharming's (PHAR) quarterly Income from Continuing Operations came in at 28009000.0 in Q2 2026, up 397.58% YoY from 5629003.8 in Q2 2025, and up 296.42% on a QoQ basis from 14260000.0 in Q1 2026.
Pharming (PHAR) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Pharming (PHAR) has 7 years of Income from Continuing Operations data on file, last reported at 28009000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 397.58% year-over-year to 28009000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 39841009.5 (up 461.17% YoY) and the FY2025 annual result came in at 2537000.0, up 121.43% from the prior year.
- Income from Continuing Operations grew to 28009000.0 in Q2 2026, from 14260000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 37900000.0 in Q4 2022 to a low of 20488000.0 in Q1 2024.
- A 5-year average of 2089555.33 and a median of 757003.4 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations plunged 603.58% — and 2025, when it jumped 1623.38%.
- Tracing PHAR's Income from Continuing Operations over 5 years: stood at 37900000.0 in 2022, then sank by 131.69% to 12012002.6 in 2023, then soared by 57.18% to 5143000.0 in 2024, then surged by 100.0% to 4.3 in 2025, then soared by 651371993.02% to 28009000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 28009000.0 (Q2 2026), 14260000.0 (Q1 2026), and 4.3 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Pharming | 824.47 Mn | 666.19 Mn | 141.47 Mn | 28.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.01 Mn |
| Mar 31, 2026 | -14.26 Mn |
| Dec 31, 2025 | 4.30 |
| Sep 30, 2025 | 26.09 Mn |
| Jun 30, 2025 | 5.63 Mn |
| Mar 31, 2025 | -13.03 Mn |
| Dec 31, 2024 | -5.14 Mn |
| Sep 30, 2024 | 1.51 Mn |
| Jun 30, 2024 | -3.02 Mn |
| Mar 31, 2024 | -20.49 Mn |
| Dec 31, 2023 | -12.01 Mn |
| Sep 30, 2023 | 3.15 Mn |
| Jun 30, 2023 | -13.29 Mn |
| Mar 31, 2023 | -18.13 Mn |
| Dec 31, 2022 | 37.90 Mn |
| Sep 30, 2022 | 9.50 Mn |
| Jun 30, 2022 | 21.59 Mn |
| Mar 31, 2022 | 3.60 Mn |
| Dec 31, 2021 | 15.19 Mn |
| Sep 30, 2021 | -17.81 Mn |